Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6)
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background Disordered differentiation and hyperproliferation of keratinocytes with inflammation are the hallmarks of psoriasis. Ligand activation of peroxisome proliferator receptor‐γ (a class of nuclear receptors) by thiazolidinediones can normalize the histologic features of psoriasis. Method In a 10‐week, double‐blind, randomized, placebo‐controlled, parallel‐group study, 70 patients with moderate to severe psoriasis received one of the following treatments: pioglitazone 15 mg, pioglitazone 30 mg or placebo. Efficacy was evaluated by observing the change in the psoriasis area and severity index (PASI) after 10 weeks of treatment. Results There was a dose‐dependent improvement in psoriasis. Median PASI scores at the end of 10 weeks were significantly reduced in the pioglitazone treatment groups as compared to the placebo‐treated group. The psoriasis lesions cleared in more than 40% of patients treated with pioglitazone as compared to 12.5% of those with placebo. The percentage reduction in mean PASI scores was 21.6%, 41.1% and 47.5% in the placebo, pioglitazone 15 mg, and 30 mg groups, respectively. No serious adverse events were detected. Conclusion This is the first report from a controlled trial demonstrating that pioglitazone could be considered as an efficacious and safe agent for the treatment of plaque psoriasis. The optimum dose and duration of pioglitazone therapy remain to be determined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb
Jiang, J., & Struhl, G. (1998) · Nature · doi:10.1038/35154 · Cited by 1,735
Orphan Nuclear Receptors: Shifting Endocrinology into Reverse
Kliewer, S. A., Lehmann, J. M., & Willson, T. M. (1999) · Science · doi:10.1126/science.284.5415.757 · Cited by 499
Michalik, L., Desvergne, B., Tan, N. S., Basu-Modak, S., Escher, P., Rieusset, J., Peters, J. M., Kaya, G., Gonzalez, F. J., Zakany, J., et al. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200011148 · Cited by 406
Cited by
Obesity and the skin: Skin physiology and skin manifestations of obesity
Yosipovitch, G., DeVore, A., & Dawn, A. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.12.004 · Cited by 524
Negrotto, L., Farez, M. F., & Correale, J. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.4807 · Cited by 198
Role of PPAR, LXR, and PXR in epidermal homeostasis and inflammation
Schmuth, M., Moosbrugger-Martinz, V., Blunder, S., & Dubrac, S. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.11.012 · Cited by 100
Metadata
- Authors
- Shafiq, N., Malhotra, S., Pandhi, P., Gupta, M., Kumar, B., & Sandhu, K.
- Venue
- International Journal of Dermatology
- Publisher
- Wiley
- Published
- 2005-03-30
- Volume
- 44
- Issue
- 4
- Pages
- 328-333
- ISSN
- 0011-9059 (ISSN-L)
- 1365-4632
- OpenAlex
- W2046429755
- Cited by
- 79
- References
- 6
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6). https://app.cochat.ai/papers/10.1111/j.1365-4632.2005.02504.x
- The paper
- Shafiq, N., Malhotra, S., Pandhi, P., Gupta, M., Kumar, B., & Sandhu, K. (2005). Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6). International Journal of Dermatology. https://doi.org/10.1111/j.1365-4632.2005.02504.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.